{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T17:06:55Z","timestamp":1768410415425,"version":"3.49.0"},"reference-count":226,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T00:00:00Z","timestamp":1604361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Bioeng. Biotechnol."],"DOI":"10.3389\/fbioe.2020.549089","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T14:58:00Z","timestamp":1604415480000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Biotechnology and Biomaterial-Based Therapeutic Strategies for Age-Related Macular Degeneration. Part I: Biomaterials-Based Drug Delivery Devices"],"prefix":"10.3389","volume":"8","author":[{"given":"Nahla","family":"Jemni-Damer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atocha","family":"Guedan-Duran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Fuentes-Andion","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nora","family":"Serrano-Bengoechea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuria","family":"Alfageme-Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Armada-Maresca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustavo V.","family":"Guinea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"P\u00e9rez-Rigueiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Rojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez-Nieto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David L.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fivos","family":"Panetsos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,11,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1097\/IAE.0b013e3181a2f42a","article-title":"Preparation, characterization, and in vivo evaluation of nanoliposomes-encapsulated bevacizumab (avastin) for intravitreal administration.","volume":"29","author":"Abrishami","year":"2009","journal-title":"Retina"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1021\/acs.jmedchem.7b01731","article-title":"The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 inhibitor specifically designed for topical ocular delivery, as a therapy for neovascular age-.","volume":"61","author":"Adams","year":"2018","journal-title":"J. Med. Chem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1517\/17425247.2012.665367","article-title":"In situ gel systems as \u201csmart\u201d carriers for sustained ocular drug delivery.","volume":"9","author":"Agrawal","year":"2012","journal-title":"Expert Opin. Drug Deliv."},{"key":"B4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/J.EJPB.2014.07.005","article-title":"Polyethylene glycol (PEG)\u2013Poly(N-isopropylacrylamide) (PNIPAAm) based thermosensitive injectable hydrogels for biomedical applications.","volume":"88","author":"Alexander","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B5","year":"2019","journal-title":"Alimera Sciences."},{"key":"B6","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.neuron.2012.06.018","article-title":"Mechanisms of age-related macular degeneration.","volume":"75","author":"Ambati","year":"2012","journal-title":"Neuron"},{"key":"B7","doi-asserted-by":"publisher","first-page":"710","DOI":"10.3109\/10717544.2014.923065","article-title":"Colloidal drug delivery system: amplify the ocular delivery.","volume":"23","author":"Ameeduzzafar","year":"2016","journal-title":"Drug Deliv."},{"key":"B8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0002-9394(02)01624-0","article-title":"A role for local inflammation in the formation of drusen in the aging eye.","volume":"134","author":"Anderson","year":"2002","journal-title":"Am. J.Ophthalmol."},{"key":"B9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1080\/21691401.2018.1478845","article-title":"Polymeric, injectable, intravitreal hydrogel devices for posterior segment applications and interventions.","volume":"46","author":"Anwary","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.preteyeres.2013.07.003","article-title":"Aging is not a disease: distinguishing age-related macular degeneration from aging.","volume":"37","author":"Ardeljan","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jconrel.2019.01.012","article-title":"Simultaneous co-delivery of neuroprotective drugs from multi-loaded PLGA microspheres for the treatment of glaucoma.","volume":"297","author":"Arranz-Romera","year":"2019","journal-title":"J. Control. Release"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.104993","article-title":"In situ antibody-loaded hydrogel for intravitreal delivery.","volume":"137","author":"Awwad","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/mabi.201700255","article-title":"Comparative study of in situ loaded antibody and PEG-Fab NIPAAM Gels.","volume":"18","author":"Awwad","year":"2018","journal-title":"Macromol. Biosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3330","DOI":"10.1002\/jps.24480","article-title":"The PK-Eye?: a novel in vitro ocular flow model for use in preclinical drug development.","volume":"104","author":"Awwad","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.5772\/64301","article-title":"An introduction to hydrogels and some recent applications","author":"Bahram","year":"2016","journal-title":"Emerging Concepts in Analysis and Applications of Hydrogels"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/bioengineering7030065","article-title":"Regulation of the ocular cell\/tissue response by implantable biomaterials and drug delivery systems.","volume":"7","author":"Baino","year":"2020","journal-title":"Bioengineering"},{"key":"B17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1089\/jop.2015.0133","article-title":"Posterior segment drug delivery devices: current and novel therapies in development.","volume":"32","author":"Bansal","year":"2016","journal-title":"J. Ocular Pharmacol. Ther."},{"key":"B18","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/anie.201610618","article-title":"Photo-modulated therapeutic protein release from a hydrogel depot using visible light.","volume":"56","author":"Basuki","year":"2017","journal-title":"Angew. Chem, Int. Ed."},{"key":"B19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/s0039-6257(00)00140-5","article-title":"The role of oxidative stress in the pathogenesis of age-related macular degeneration.","volume":"45","author":"Beatty","year":"2000","journal-title":"Survey Ophthalmol."},{"key":"B20","article-title":"Development of precisely-engineered biodegradable drug delivery systems for posterior ocular drug delivery: PRINT\u00ae PLGA extended release implants for anti-VEGF biologics.","volume":"55","author":"Benjamin","year":"2014","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B21","doi-asserted-by":"publisher","first-page":"5355","DOI":"10.1021\/nl302747y","article-title":"Nanostructured thin film polymer devices for constant-rate protein delivery NIH public access.","volume":"12","author":"Bernards","year":"2012","journal-title":"Nano Lett."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1111\/AOS.12020","article-title":"Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up \u2013 The SOLO study.","volume":"91","author":"Bezatis","year":"2013","journal-title":"Acta Ophthalmol."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-019-1474-0","article-title":"An in vitro assessment of thermo-reversible gel formulation containing sunitinib nanoparticles for neovascular age-related macular degeneration.","volume":"20","author":"Bhatt","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1001\/archophthalmol.2009.304","article-title":"Risk of endophthalmitis after intravitreal drug injection when topical antibiotics are not required: the diabetic retinopathy clinical research network laser-ranibizumab-triamcinolone clinical trials.","volume":"127","author":"Bhavsar","year":"2009","journal-title":"Arch. Ophthalmol."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S13775","article-title":"Critical appraisal of the clinical utility of the dexamethasone intravitreal implant (Ozurdex&reg) for the treatment of macular edema related to branch retinal vein occlusion or central retinal vein occlusion.","volume":"5","author":"Blumenkranz","year":"2011","journal-title":"Clin. Ophthalmol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/j.addr.2006.07.026","article-title":"Intraocular implants for extended drug delivery: therapeutic applications.","volume":"58","author":"Bourges","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","article-title":"Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients.","volume":"31","author":"Boyer","year":"2011","journal-title":"Retina"},{"key":"B28","first-page":"1443","article-title":"Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration additional information regarding baseline lesion composition\u2019s impact on vision outcomes-TAP Report No. 3 treatment of age-related macular degeneration with photodynamic therapy (TAP) study group\u2217.","volume":"120","author":"Bressler","year":"2002","journal-title":"Arch. Oftalmol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.preteyeres.2009.07.001","article-title":"Cellular signaling and factors involved in M\u00fcller cell gliosis: neuroprotective and detrimental effects.","volume":"28","author":"Bringmann","year":"2009","journal-title":"Prog. Retin. Eye Res."},{"key":"B30","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0039-6257(96)82027-3","article-title":"Preclinical evaluation of brimonidine.","volume":"41","author":"Burke","year":"1996","journal-title":"Survey Ophthalmol."},{"key":"B31","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","article-title":"Treatment of posterior uveitis with a fluocinolone acetonide implant three-year clinical trial results.","volume":"126","author":"Callanan","year":"2008","journal-title":"Arch Ophthalmol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/978-1-4614-4711-5_3","article-title":"The blood-retina barrier tight junctions and barrier modulation.","volume":"763","author":"Campbell","year":"2013","journal-title":"Adv. Exp. Med. Biol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","article-title":"Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular Edema.","volume":"119","author":"Campochiaro","year":"2012","journal-title":"Ophthalmology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"626.e2","DOI":"10.1016\/j.ophtha.2010.12.028","article-title":"Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema.","volume":"118","author":"Campochiaro","year":"2011","journal-title":"Ophthalmology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.ophtha.2019.03.036","article-title":"The port delivery system with ranibizumab for neovascular age-related macular degeneration: results from the randomized phase 2 ladder clinical trial.","volume":"126","author":"Campochiaro","year":"2019","journal-title":"Ophthalmology"},{"key":"B36","first-page":"46","article-title":"Origin of the diseases suffered by the aged, today: behavior, life style, diet, greater life expectancy.","volume":"57","author":"Casado","year":"2009","journal-title":"Servir"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.drudis.2019.05.037","article-title":"Hydrogels for sustained delivery of biologics to the back of the eye.","volume":"24","author":"Chang","year":"2019","journal-title":"Drug Discov. Today"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-11-98","article-title":"Neuroinflammation and M2 microglia: the good, the bad, and the inflamed.","volume":"11","author":"Cherry","year":"2014","journal-title":"J. Neuroinflamm."},{"key":"B39","article-title":"20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) - Full Text View","year":""},{"key":"B40","year":"","journal-title":"A Phase III Study to Evaluate the Port Delivery System With Ranibizumab Compared With Monthly Ranibizumab Injections in Participants With Wet Age-Related Macular Degeneration - Full Text View."},{"key":"B41","year":"","journal-title":"A Safety, and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration - Full Text View."},{"key":"B42","year":"","journal-title":"Combined Ranibizumab, and Iluvien for Diabetic Macular Oedema - Full Text View."},{"key":"B43","year":"","journal-title":"Extension Study for the Port Delivery System With Ranibizumab(Portal) - Full Text View."},{"key":"B44","year":"","journal-title":"Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study - Full Text View."},{"key":"B45","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/bs.pmbts.2015.06.005","article-title":"Chapter twenty-six - A2E and lipofuscin.","volume":"134","author":"Crouch","year":"2015","journal-title":"Prog. Mol. Biol. Transl. Sci."},{"key":"B46","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.preteyeres.2014.07.001","article-title":"Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases.","volume":"43","author":"Cuenca","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"B47","doi-asserted-by":"publisher","first-page":"3","DOI":"10.5301\/EJO.2010.6049","article-title":"Blood-retinal barrier.","volume":"21","author":"Cunha-Vaz","year":"2011","journal-title":"Eur. J. Ophthalmol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1157\/13090016","article-title":"Epidemiolog\u00eda de la degeneraci\u00f3n macular asociada con la edad. Situaci\u00f3n en Espa\u00f1a.","volume":"38","author":"Dami\u00e1n","year":"2006","journal-title":"Aten. Primaria"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1186\/s40101-016-0091-9","article-title":"Light-sensitive brain pathways and aging.","volume":"35","author":"Daneault","year":"2016","journal-title":"J. Physiol. Anthropol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/smll.201303433","article-title":"Topical delivery of avastin to the posterior segment of the eye in vivo using annexin A5-associated liposomes.","volume":"10","author":"Davis","year":"2014","journal-title":"Small"},{"key":"B51","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/B978-0-12-814423-7.00002-2","article-title":"Physicochemical aspects to be considered in pharmaceutical product development","author":"Deb","year":"2018","journal-title":"Dosage Form Design Considerations"},{"key":"B52","doi-asserted-by":"publisher","first-page":"493","DOI":"10.22608\/apo.2017251","article-title":"Updates on the epidemiology of age-related macular degeneration.","volume":"6","author":"Degeneration","year":"2017","journal-title":"Asia Pacific J. Ophthalmol."},{"key":"B53","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/J.DRUDIS.2007.11.002","article-title":"Current and future ophthalmic drug delivery systems: a shift to the posterior segment.","volume":"13","author":"del Amo","year":"2008","journal-title":"Drug Discov. Today"},{"key":"B54","author":"Desai","year":"2014","journal-title":"Zordera."},{"key":"B55","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1007\/s11095-013-1195-0","article-title":"The effect of glutathione as chain transfer agent in PNIPAAm-based thermo-responsive hydrogels for controlled release of proteins.","volume":"31","author":"Drapala","year":"2014","journal-title":"Pharm. Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.survophthal.2004.12.006","article-title":"Applications of liposomes in ophthalmology.","volume":"50","author":"Ebrahim","year":"2005","journal-title":"Surv. Ophthalmol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1080\/17425255.2017.1404987","article-title":"Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes.","volume":"13","author":"Edington","year":"2017","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"B58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bjo.2003.019927","article-title":"Causes of visual impairment in people aged 75 years and older in Britain: an add-on study to the MRC Trial of Assessment and Management of Older People in the Community.","volume":"88","author":"Evans","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"B59","year":"2020","journal-title":"Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMD."},{"key":"B60","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","article-title":"Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature.","volume":"27","author":"Falavarjani","year":"2013","journal-title":"Eye"},{"key":"B61","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2165\/00002512-200623050-00006","article-title":"Verteporfin: a review of its use in the management of subfoveal choroidal neovascularisation.","volume":"23","author":"Fenton","year":"2006","journal-title":"Drugs Aging"},{"key":"B62","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1001\/archopht.123.11.1570","article-title":"A simplified severity scare for age-related macular degeneration: AREDS Report no.18.","volume":"123","author":"Ferris","year":"2005","journal-title":"Arch Ophthalmol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.ophtha.2017.08.038","article-title":"The progression of geographic atrophy secondary to age-related macular degeneration.","volume":"125","author":"Fleckenstein","year":"2018","journal-title":"Ophthalmology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"9540","DOI":"10.1021\/ja102595j","article-title":"UV and near-IR triggered release from polymeric nanoparticles.","volume":"132","author":"Fomina","year":"2010","journal-title":"J. the Am. Chem. Soc."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1517\/14656566.2013.787410","article-title":"An update on the pharmacotherapy of neovascular age-related macular degeneration.","volume":"14","author":"Freund","year":"2013","journal-title":"Expert Opin. Pharm."},{"key":"B66","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archopht.122.4.564","article-title":"Prevalence of age-related macular degeneration in the US population.","volume":"122","author":"Friedman","year":"2004","journal-title":"Arch. Ophthalmol."},{"key":"B67","author":"Friedman","year":"2012","journal-title":"Vision Problems in the U.S"},{"key":"B68","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/jop.2016.0083","article-title":"Binding to ocular albumin as a half-life extension principle for intravitreally injected drugs: evidence from mechanistic rat and rabbit studies.","volume":"33","author":"Fuchs","year":"2017","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1002\/jbm.b.34048","article-title":"Sterilization of hydrogels for biomedical applications: a review.","volume":"106","author":"Galante","year":"2018","journal-title":"J. Biomed. Mater. Res. Part B Appl. Biomater."},{"key":"B70","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1001\/archopht.120.6.797","article-title":"Up-regulation of brain-derived neurotrophic factor expression by brimonidine in rat retinal ganglion cells.","volume":"120","author":"Gao","year":"2002","journal-title":"Arch. Ophthalmol."},{"key":"B71","first-page":"24","article-title":"Degeneracio\u00ecn macular asociada a la edad (DMAE). Gui\u00eca cli\u00ecnica optome\u00ectrica, a partir de estudios basados en la evidencia.","volume":"487","author":"Garci\u00eca","year":"2013","journal-title":"Gaceta de Optometri\u00eca y O\u00ecptica Ofta\u00eclmica"},{"key":"B72","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1007\/s11095-008-9694-0","article-title":"Recent perspectives in ocular drug delivery.","volume":"26","author":"Gaudana","year":"2009","journal-title":"Pharm. Res."},{"key":"B73","first-page":"191","article-title":"Implantable posterior segment drug delivery devices; novel alternatives to currently available treatments.","volume":"4","author":"Ghasemi Falavarjani","year":"2009","journal-title":"J. Ophthalmic Vis. Res."},{"key":"B74","first-page":"119","article-title":"Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization.","volume":"8","author":"Grossniklaus","year":"2002","journal-title":"Mol. Vis."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.3.4.1","article-title":"One-year feasibility study of replenish micropump for intravitreal drug delivery: a pilot Study.","volume":"3","author":"Guti\u00e9rrez-Hern\u00e1ndez","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B76","first-page":"317","article-title":"Sustained release intraocular drug delivery devices for treatment of uveitis.","volume":"6","author":"Haghjou","year":"2011","journal-title":"J. Ophthalmic Vis. Res."},{"key":"B77","doi-asserted-by":"publisher","first-page":"1134.e3","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"B78","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/mabi.201400379","article-title":"Protein compatibility of selected cross-linking reactions for hydrogels.","volume":"15","author":"Hammer","year":"2015","journal-title":"Macromol. Biosci."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11262-1","article-title":"A systems biology approach towards understanding and treating non-neovascular age-related macular degeneration.","volume":"10","author":"Handa","year":"2019","journal-title":"Nat. Commun."},{"key":"B80","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1359-0286(02)00117-1","article-title":"Biodegradable nanoparticles for drug delivery and targeting.","volume":"6","author":"Hans","year":"2002","journal-title":"Curr. Opin. Solid State Mater. Sci."},{"key":"B81","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.arr.2015.09.002","article-title":"RPE necroptosis in response to oxidative stress and in AMD.","volume":"24","author":"Hanus","year":"2015","journal-title":"Ageing Res. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.preteyeres.2014.04.002","article-title":"The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies.","volume":"42","author":"Herrero-Vanrell","year":"2014","journal-title":"Prog. Retin. Eye Res."},{"key":"B83","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0169-409X(01)00200-9","article-title":"Biodegradable microspheres for vitreoretinal drug delivery.","volume":"52","author":"Herrero-Vanrell","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B84","doi-asserted-by":"publisher","first-page":"495","DOI":"10.2147\/IJN.S30725","article-title":"Liposomes and nanotechnology in drug development: focus on ocular targets.","volume":"8","author":"Honda","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"B85","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1023\/A:1015948829632","article-title":"Release of human serum albumin from poly(lactide-co-glycolide) microspheres.","volume":"7","author":"Hora","year":"1990","journal-title":"Pharm. Res."},{"key":"B86","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3233\/THC-199015","article-title":"Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits.","volume":"27","author":"Hu","year":"2019","journal-title":"Technol Health Care"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.3.6.5","article-title":"Implantable micropump for drug delivery in patients with diabetic macular edema.","volume":"3","author":"Humayun","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jconrel.2015.01.001","article-title":"Light-responsive nanoparticle depot to control release of a small molecule angiogenesis inhibitor in the posterior segment of the eye.","volume":"200","author":"Huu","year":"2015","journal-title":"J. Control. Release?"},{"key":"B89","year":"2017","journal-title":"Global Vision Database Maps. Global Vision Database Maps."},{"key":"B90","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jconrel.2018.06.031","article-title":"Polymer-based carriers for ophthalmic drug delivery.","volume":"285","author":"Imperiale","year":"2018","journal-title":"J. Control. Release"},{"key":"B91","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1001\/jamaophthalmol.2017.1571","article-title":"Oral tyrosine kinase inhibitor for neovascular age-related macular degeneration: a phase 1 dose-escalation study.","volume":"135","author":"Jackson","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"B92","first-page":"3569","article-title":"Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device.","volume":"41","author":"Jaffe","year":"2000","journal-title":"Inves. Ophthalmol. Vis. Sci."},{"key":"B93","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1097\/00006982-200410000-00002","article-title":"Risks of intravitreous injection: a comprehensive review.","volume":"24","author":"Jager","year":"2004","journal-title":"Retina"},{"key":"B94","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1056\/NEJMra0801537","article-title":"Age-related macular degeneration.","volume":"358","author":"Jager","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.mam.2012.03.009","article-title":"Consequences of oxidative stress in age-related macular degeneration.","volume":"33","author":"Jarrett","year":"2012","journal-title":"Mol. Aspects Med."},{"key":"B96","article-title":"Pharmacokinetics of a 6 month sustained hydrogel delivery system for tyrosine kinase inhibitors in dutch belted rabbits.","volume":"58","author":"Jarrett","year":"2017","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B97","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jphysparis.2013.10.001","article-title":"Mapping the primate lateral geniculate nucleus: a review of experiments and methods.","volume":"108","author":"Jeffries","year":"2014","journal-title":"J. Physiol. Paris"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1002\/mame.201900087","article-title":"Near-infrared light-triggered dual drug release using gold nanorod-embedded thermosensitive nanogel-crosslinked hydrogels.","volume":"304","author":"Jiang","year":"2019","journal-title":"Macromol. Mater. Eng."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/21691401.2018.1478845","article-title":"Polymeric, injectable, intravitreal hydrogel devices for posterior segment applications and interventions.","volume":"46","author":"Journal","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B100","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.eurger.2014.09.007","article-title":"Age related macular degeneration \u2013 challenge for future?: pathogenesis and new perspectives for the treatment.","volume":"6","author":"Kabiesz","year":"2015","journal-title":"Eur. Geriatr. Med."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1097\/00000542-200506000-00018","article-title":"Opposing effects of isoflurane and sevoflurane on neurogenic pulmonary edema development in an animal model.","volume":"102","author":"Kandatsu","year":"2005","journal-title":"Anesthesiology"},{"key":"B102","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","article-title":"Iluvien TM?: a new sustained delivery technology for posterior eye disease.","volume":"5","author":"Kane","year":"2008","journal-title":"Expert Opin. Drug Deliv."},{"key":"B103","first-page":"206","article-title":"Thermoresponsive hydrogels as a new ocular drug delivery platform to the posterior segment of the eye.","volume":"106","author":"Kang Derwent","year":"2008","journal-title":"Trans. Am. Ophthalmol. Soc."},{"key":"B104","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1080\/17425247.2016.1227785","article-title":"Extended ocular drug delivery systems for the anterior and posterior segments: biomaterial options and applications.","volume":"14","author":"Kang-Mieler","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1517\/17425247.2014.935338","article-title":"Advances in ocular drug delivery: emphasis on the posterior segment.","volume":"11","author":"Kang-Mieler","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"B106","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41433-020-0809-0","article-title":"Advances in ocular drug delivery systems.","volume":"34","author":"Kang-Mieler","year":"2020","journal-title":"Eye"},{"key":"B107","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1002\/jbm.a.31811","article-title":"Effects of sterilization on poly(ethylene glycol) hydrogels.","volume":"87","author":"Kanjickal","year":"2008","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1002\/bit.23105","article-title":"Application of a dense gas technique for sterilizing soft biomaterials.","volume":"108","author":"Karajanagi","year":"2011","journal-title":"Biotechnol. Bioeng."},{"key":"B109","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1136\/bjo.2005.073643","article-title":"Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation.","volume":"90","author":"Khan","year":"2006","journal-title":"Br. J. Ophthalmol."},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/srep44364","article-title":"Effects of silk fibroin in murine dry eye.","volume":"7","author":"Kim","year":"2017","journal-title":"Nat. Publ. Group"},{"key":"B111","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/j.1755-3768.2011.02179.x","article-title":"Molecular mechanisms of retinal pigment epithelium damage and development of age-related macular degeneration.","volume":"90","author":"Kinnunen","year":"2012","journal-title":"Acta Ophthalmol."},{"key":"B112","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.ejpb.2015.05.016","article-title":"Hydrogels in ophthalmic applications.","volume":"95","author":"Kirchhof","year":"","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B113","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/J.EJPB.2015.07.024","article-title":"Diels\u2013Alder hydrogels with enhanced stability: first step toward controlled release of bevacizumab.","volume":"96","author":"Kirchhof","year":"","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B114","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/archophthalmol.2010.318","article-title":"Prevalence of age-related macular degeneration in the us population.","volume":"129","author":"Klein","year":"2011","journal-title":"Arch. Ophthalmol."},{"key":"B115","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1126\/science.1109557","article-title":"Complement factor H polymorphism in age-related macular degeneration.","volume":"308","author":"Klein","year":"2005","journal-title":"Science"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.joca.2020.02.061","article-title":"Intra-articular drug depots for controlled release of heavy chain only antibodies blocking joint inflammation.","volume":"28","author":"Koerselman","year":"2020","journal-title":"Osteoarthr. Cartil."},{"key":"B117","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/11530970-000000000-00000","article-title":"Biodegradable intraocular therapies for retinal disorders.","volume":"27","author":"Kuno","year":"2010","journal-title":"Drugs Aging"},{"key":"B118","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/archopht.125.3.309","article-title":"Randomized controlled study of an intravitreous dexamethasone drug delivery system in patients with persistent macular edema.","volume":"125","author":"Kuppermann","year":"2007","journal-title":"Arch. Ophthalmol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2165\/00002512-200219020-00003","article-title":"Age-related macular degeneration.","volume":"19","author":"Lacour","year":"2002","journal-title":"Drugs Aging"},{"key":"B120","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s10856-013-4961-y","article-title":"Influence of solvent composition on the performance of carbodiimide cross-linked gelatin carriers for retinal sheet delivery.","volume":"24","author":"Lai","year":"2013","journal-title":"J. Mater. Sci."},{"key":"B121","doi-asserted-by":"publisher","first-page":"3230","DOI":"10.1167\/iovs.06-1305","article-title":"Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal peptide encapsulated in liposomes.","volume":"48","author":"Lajavardi","year":"2007","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B122","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s13346-016-0298-7","article-title":"In vivo and in vitro sustained release of ranibizumab from a nanoporous thin-film device.","volume":"6","author":"Lance","year":"2016","journal-title":"Drug Deliv. Transl. Res."},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.15-17757","article-title":"In vitro and in vivo sustained zero-order delivery of rapamycin (Sirolimus) from a biodegradable intraocular device.","volume":"56","author":"Lance","year":"2015","journal-title":"Invest. Opthalmol. Vis. Sci."},{"key":"B124","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2174\/1874364101206010054","article-title":"Controlled release of bevacizumab through nanospheres for extended treatment of age-related macular degeneration.","volume":"6","author":"Li","year":"2012","journal-title":"Open Ophthalmol. J."},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/natrevmats.2016.71","article-title":"Designing hydrogels for controlled drug delivery.","volume":"1","author":"Li","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"B126","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ajo.2011.09.013","article-title":"Delay to treatment and visual outcomes in patients treated with anti-vascular endothelial growth factor for age-related macular degeneration.","volume":"153","author":"Lim","year":"2012","journal-title":"Am. J. Ophthalmol."},{"key":"B127","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1136\/bjophthalmol-2014-306002","article-title":"One year results of a phase 1 study of the safety and tolerability of combination therapy using sustained release intravitreal triamcinolone acetonide and ranibizumab for subfoveal neovascular AMD.","volume":"99","author":"Lim","year":"2015","journal-title":"Br. J. Ophthalmol."},{"key":"B128","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0002-9394(98)00443-7","article-title":"Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis.","volume":"127","author":"Lim","year":"1999","journal-title":"Am. J. Ophthalmol."},{"key":"B129","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/nature05292","article-title":"Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases.","volume":"443","author":"Lin","year":"2006","journal-title":"Nature"},{"key":"B130","doi-asserted-by":"publisher","first-page":"89","DOI":"10.4155\/tde-2016-0060","article-title":"Recent advances in light-responsive on-demand drug-delivery systems.","volume":"8","author":"Linsley","year":"2017","journal-title":"Ther. Deliv."},{"key":"B131","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.04.012","article-title":"Highly bioactive, bevacizumab-loaded, sustained-release PLGA\/PCADK microspheres for intravitreal therapy in ocular diseases.","volume":"563","author":"Liu","year":"","journal-title":"Int. J. Pharm."},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.8.1.12","article-title":"Characterization of biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of ranibizumab.","volume":"8","author":"Liu","year":"","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B133","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/02713683.2018.1533983","article-title":"Biodegradable microsphere-hydrogel ocular drug delivery system for controlled and extended release of bioactive aflibercept in vitro.","volume":"44","author":"Liu","year":"","journal-title":"Curr. Eye Res."},{"key":"B134","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s10544-009-9313-9","article-title":"A passive MEMS drug delivery pump for treatment of ocular diseases.","volume":"11","author":"Lo","year":"2009","journal-title":"Biomed. Microdev."},{"key":"B135","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/J.EJPB.2014.12.029","article-title":"Silk hydrogels for sustained ocular delivery of anti-vascular endothelial growth factor (anti-VEGF) therapeutics.","volume":"95","author":"Lovett","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.7.4.21","article-title":"A controlled release system for long-acting intravitreal delivery of small molecules.","volume":"7","author":"Machinaga","year":"2018","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B137","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2174\/1389450053765914","article-title":"Colloidal carriers for ophthalmic drug delivery.","volume":"6","author":"Mainardes","year":"2005","journal-title":"Curr. Drug Targ."},{"key":"B138","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jconrel.2017.01.012","article-title":"Polymeric micelles for ocular drug delivery?: from structural frameworks to recent preclinical studies.","volume":"248","author":"Mandal","year":"2017","journal-title":"J. Control. Release"},{"key":"B139","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.addr.2018.01.008","article-title":"Ocular delivery of proteins and peptides: challenges and novel formulation approaches.","volume":"126","author":"Mandal","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"B140","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/jps.21445","article-title":"Insulin loaded PLGA microspheres: effect of zinc salts on encapsulation, release, and stability.","volume":"98","author":"Manoharan","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"B141","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1017\/S1740925X12000014","article-title":"Microglia and neuronal cell death.","volume":"7","author":"Mar\u00edn-Teva","year":"2011","journal-title":"Neuron Glia Biol."},{"key":"B142","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.ophtha.2012.03.053","article-title":"Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration.","volume":"119","author":"Martin","year":"2012","journal-title":"Ophthalmology"},{"key":"B143","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1097\/IAE.0b013e3181633fee","article-title":"Incidence of acute onset endophthalmitis following intravitreal bevacizumab (avastin) injection.","volume":"28","author":"Mason","year":"2008","journal-title":"Retina"},{"key":"B144","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.ijpharm.2014.06.029","article-title":"Thermoresponsive polymers: insights into decisive hydrogel characteristics, mechanisms of gelation, and promising biomedical applications.","volume":"472","author":"Matanovi\u0107","year":"2014","journal-title":"Int. J. Pharm."},{"key":"B145","first-page":"82","article-title":"Age-related macular degeneration.","volume":"74","author":"McConnell","year":"2005","journal-title":"Ulster Med. J."},{"key":"B146","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1001\/jamaophthalmol.2013.5002","article-title":"Initial exploration of oral pazopanib in healthy participants and patients with age-related macular degeneration.","volume":"131","author":"McLaughlin","year":"2013","journal-title":"JAMA Ophthalmol."},{"key":"B147","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/sj.bjp.0707130","article-title":"Nanoparticles: pharmacological and toxicological significance.","volume":"150","author":"Medina","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B148","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/S0142-9612(02)00084-4","article-title":"Chitin\/PLGA blend microspheres as a biodegradable drug-delivery system: phase-separation, degradation and release behavior.","volume":"23","author":"Mi","year":"2002","journal-title":"Biomaterials"},{"key":"B149","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/J.EURGER.2014.09.007","article-title":"Age related macular degeneration \u2013 challenge for future: pathogenesis and new perspectives for the treatment.","volume":"6","author":"Michalska-Ma\u0142ecka","year":"2015","journal-title":"Eur. Geriatr. Med."},{"key":"B150","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/0005-2736(89)90307-6","article-title":"Serum opsonins and phagocytosis of saturated and unsaturated phospholipid liposomes.","volume":"984","author":"Moghimi","year":"1989","journal-title":"Biochim. Biophys. Acta"},{"key":"B151","first-page":"1785","article-title":"Microspheres of Biodegradable Polymers as a Drug-Delivery System in the Vitreous.","volume":"32","author":"Morirero","year":"1991","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B152","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1080\/10717544.2018.1474967","article-title":"Multivesicular liposomes for sustained release of bevacizumab in treating laser-induced choroidal neovascularization.","volume":"25","author":"Mu","year":"2018","journal-title":"Drug Deliv."},{"key":"B153","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1089\/adt.2019.920","article-title":"Axitinib-loaded Poly(Lactic-Co-Glycolic Acid) nanoparticles for age-related macular degeneration: formulation development and in vitro characterization.","volume":"17","author":"Narvekar","year":"2019","journal-title":"Assay Drug Dev. Technol."},{"key":"B154","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1111\/j.1469-7580.2010.01330.x","article-title":"Astrocyte phenotypes and their relationship to myelination.","volume":"219","author":"Nash","year":"2011","journal-title":"J. Anat."},{"key":"B155","first-page":"10","article-title":"Improving outcomes: inophthalmology via sustained drug delivery.","volume":"48","author":"Navratil","year":"2014","journal-title":"ONdrugDelivery"},{"key":"B156","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.biopha.2018.08.138","article-title":"Biomedicine & Pharmacotherapy A review on recent drug delivery systems for posterior segment of eye.","volume":"107","author":"Nayak","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"B157","first-page":"353","article-title":"Age-related macular degeneration (AMD): pathogenesis and therapy.","volume":"58","author":"Nowak","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"B158","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1073\/pnas.0408835103","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization.","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proc. Natil. Acad. Sci. U.S.A."},{"key":"B159","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.ajo.2007.06.025","article-title":"Age-related macular degeneration and the immune response: implications for therapy.","volume":"144","author":"Nussenblatt","year":"2007","journal-title":"Am. J. Ophthalmol."},{"key":"B160","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1586\/17512433.2016.1160778","article-title":"Leveraging the attributes of biologics and small molecules, and releasing the bottlenecks: a new wave of revolution in drug development.","volume":"9","author":"Oo","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"B161","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1080\/02713683.2017.1302590","article-title":"In vivo efficacy of an injectable microsphere-hydrogel ocular drug delivery system.","volume":"42","author":"Osswald","year":"2017","journal-title":"Curr. Eye Res."},{"key":"B162","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s10439-015-1314-7","article-title":"Controlled and extended release of a model protein from a microsphere-hydrogel drug delivery system.","volume":"43","author":"Osswald","year":"2015","journal-title":"Ann. Biomed. Eng."},{"key":"B163","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.3109\/02713683.2015.1101140","article-title":"Controlled and extended in vitro release of bioactive anti-vascular endothelial growth factors from a microsphere-hydrogel drug delivery system.","volume":"41","author":"Osswald","year":"2016","journal-title":"Curr. Eye Res."},{"key":"B164","year":"2020","journal-title":"(anti-VEGF antibody implant) \u2013 Ocular Therapeutix."},{"key":"B165","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1089\/jop.2010.0158","article-title":"Comparison of long-acting bevacizumab formulations in the treatment of choroidal neovascularization in a rat model.","volume":"27","author":"Pan","year":"2011","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"B166","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1080\/21691401.2016.1243545","article-title":"Chitosan-coated PLGA nanoparticles of bevacizumab as novel drug delivery to target retina: optimization, characterization, and in vitro toxicity evaluation.","volume":"45","author":"Pandit","year":"2017","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"B167","doi-asserted-by":"publisher","first-page":"47","DOI":"10.5497\/wjp.v2.i2.47","article-title":"Ocular drug delivery systems: an overview.","volume":"2","author":"Patel","year":"2013","journal-title":"World J. Pharmacol."},{"key":"B168","doi-asserted-by":"publisher","first-page":"2744","DOI":"10.1039\/c1lc20134d","article-title":"On-demand controlled release of docetaxel from a battery-less MEMS drug delivery device.","volume":"11","author":"Pirmoradi","year":"2011","journal-title":"Lab Chip"},{"key":"B169","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.pneurobio.2010.06.009","article-title":"Microglia and neuroprotection: from in vitro studies to therapeutic applications.","volume":"92","author":"Polazzi","year":"2010","journal-title":"Prog. Neurobiol."},{"key":"B170","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/B978-0-08-100907-9.00003-9","article-title":"Coaxial electrospinning of nanofibers","author":"Qin","year":"2017","journal-title":"Electrospun Nanofibers"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1021\/acs.molpharmaceut.8b01319","article-title":"Fenofibrate-loaded biodegradable nanoparticles for the treatment of experimental diabetic retinopathy and neovascular age-related macular degeneration.","volume":"16","author":"Qiu","year":"2019","journal-title":"Mol. Pharm."},{"key":"B172","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1159\/000342160","article-title":"Repeated intravitreal dexamethasone implant (ozurdex\u00ae) for retinal vein occlusion.","volume":"229","author":"Querques","year":"2013","journal-title":"Ophthalmologica"},{"key":"B173","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.drudis.2016.10.015","article-title":"Protein delivery to the back of the eye: barriers, carriers and stability of anti-VEGF proteins.","volume":"22","author":"Radhakrishnan","year":"2017","journal-title":"Drug Discov. Today"},{"key":"B174","article-title":"Advances in pharmaceutical product development and research","author":"Rakesh","year":"2019","journal-title":"Biomaterials and Bionanotechnology"},{"key":"B175","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.pneurobio.2018.05.006","article-title":"Retinal microglia \u2013 A key player in healthy and diseased retina.","volume":"173","author":"Rathnasamy","year":"2019","journal-title":"Prog. Neurobiol."},{"key":"B176","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/cge.12206","article-title":"Age-related macular degeneration-clinical review and genetics update.","volume":"84","author":"Ratnapriya","year":"2013","journal-title":"Clin. Genet."},{"key":"B177","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1167\/iovs.13-13120","article-title":"Biocompatible reverse thermal gel sustains the release of intravitreal bevacizumab in vivo.","volume":"55","author":"Rauck","year":"2013","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B178","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/386671a0","article-title":"Mechanisms of angiogenesis.","volume":"386","author":"Risau","year":"1997","journal-title":"Nature"},{"key":"B179","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/hmg\/ddi353","article-title":"Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration, contributing independently of complement factor H to disease risk.","volume":"14","author":"Rivera","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B180","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coph.2017.08.003","article-title":"Drug-device combination approaches for delivery to the eye.","volume":"36","author":"Rupenthal","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"B181","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.drudis.2007.10.021","article-title":"Nanotechnology in ocular drug delivery.","volume":"13","author":"Sahoo","year":"2008","journal-title":"Drug Discov. Today"},{"key":"B182","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1159\/000055638","article-title":"Effect of particle size of polymeric nanospheres on intravitreal kinetics.","volume":"33","author":"Sakurai","year":"2001","journal-title":"Ophthalmic Res."},{"key":"B183","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.actbio.2016.07.051","article-title":"Biomimetic hydrogel with tunable mechanical properties for vitreous substitutes.","volume":"43","author":"Santhanam","year":"2016","journal-title":"Acta Biomater."},{"key":"B184","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1089\/ten.tec.2008.0422","article-title":"Fabrication of nonwoven coaxial fiber meshes by electrospinning.","volume":"15","author":"Saraf","year":"2009","journal-title":"Tissue Eng. Part C"},{"key":"B185","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.msec.2015.07.027","article-title":"Polycaprolactone thin-film drug delivery systems: empirical and predictive models for device design.","volume":"57","author":"Schlesinger","year":"2015","journal-title":"Mater. Sci. Eng. C"},{"key":"B186","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/OPTH.S79785","article-title":"A novel intravitreal fluocinolone acetonide implant (Iluvien\u00ae) in the treatment of patients with chronic diabetic macular edema that is insufficiently responsive to other medical treatment options: a case series.","volume":"9","author":"Schmit-Eilenberger","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"B187","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41433-020-0770-y","article-title":"Use of biomaterials for sustained delivery of anti-VEGF to treat retinal diseases.","volume":"34","author":"Seah","year":"2020","journal-title":"Eye"},{"key":"B188","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.medici.2016.02.004","article-title":"Genetic factors associated with the development of age-related macular degeneration.","volume":"52","author":"Sergejeva","year":"2016","journal-title":"Medicina"},{"key":"B189","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1586\/eop.09.70","article-title":"Drug delivery to the posterior segment of the eye for pharmacologic therapy.","volume":"5","author":"Shah","year":"2010","journal-title":"Expert Rev. Ophthalmol."},{"key":"B190","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1517\/17425247.2014.902047","article-title":"Therapeutic applications of hydrogels in oral drug delivery.","volume":"11","author":"Sharpe","year":"2014","journal-title":"Expert Opin. Drug Deliv."},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-018-2498-y","article-title":"Targeted ocular drug delivery with pharmacokinetic\/pharmacodynamic considerations.","volume":"35","author":"Shen","year":"2018","journal-title":"Pharm. Res."},{"key":"B192","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1097\/IAE.0000000000001575","article-title":"Choroidal neovascularization.","volume":"37","author":"Spaide","year":"2017","journal-title":"Retina"},{"key":"B193","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1021\/acs.biomac.5b01091","article-title":"Recent progress in using biomaterials as vitreous substitutes.","volume":"16","author":"Su","year":"2015","journal-title":"Biomacromolecules"},{"key":"B194","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1097\/IAE.0000000000000008","article-title":"Endophthalmitis associated with intravitreal injections.","volume":"34","author":"Tabandeh","year":"2014","journal-title":"Retina"},{"key":"B195","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1248\/bpb.b16-00437","article-title":"Development of a sustainable release system for a ranibizumab biosimilar using Poly(lactic-co-glycolic acid) biodegradable polymerbased microparticles as a platform.","volume":"40","author":"Tanetsugu","year":"2017","journal-title":"Biol. Pharm. Bull."},{"key":"B196","author":"Tang","year":"2015","journal-title":"Electrospinning: Principles, Practice and Possibilities."},{"key":"B197","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s12035-014-9070-5","article-title":"Differential roles of M1 and M2 microglia in neurodegenerative diseases.","volume":"53","author":"Tang","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"B198","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.cell.2012.03.036","article-title":"DICER1 Loss and Alu RNA induce age-related macular degeneration via the NLRP3 Inflammasome and MyD88.","volume":"149","author":"Tarallo","year":"2012","journal-title":"Cell"},{"key":"B199","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/sj.eye.6701978","article-title":"Smoking and age-related macular degeneration: a review of association.","volume":"19","author":"Thornton","year":"2005","journal-title":"Eye"},{"key":"B200","doi-asserted-by":"crossref","DOI":"10.1002\/9781118644591","author":"Tiwari","year":"2013","journal-title":"Nanomaterials in Drug Delivery, Imaging, and Tissue Engineering."},{"key":"B201","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1016\/j.biomaterials.2011.01.058","article-title":"The effects of cross-linked thermo-responsive PNIPAAm-based hydrogel injection on retinal function.","volume":"32","author":"Turturro","year":"2011","journal-title":"Biomaterials"},{"key":"B202","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.ejps.2013.07.014","article-title":"The protective effect of albumin on bevacizumab activity and stability in PLGA nanoparticles intended for retinal and choroidal neovascularization treatments.","volume":"50","author":"Varshochian","year":"2013","journal-title":"Eur. J. of Pharm. Sci."},{"key":"B203","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1002\/jbm.a.35446","article-title":"Albuminated PLGA nanoparticles containing bevacizumab intended for ocular neovascularization treatment.","volume":"103","author":"Varshochian","year":"2015","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"B204","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1111\/bph.13426","article-title":"Microglia antioxidant systems and redox signalling.","volume":"174","author":"Vilhardt","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"B205","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1080\/17425247.2016.1213240","article-title":"Current advances in the treatment of neovascular age-related macular degeneration.","volume":"14","author":"Villegas","year":"2017","journal-title":"Expert Opin. Drug Deliv."},{"key":"B206","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1021\/bm2009558","article-title":"Extended release of bevacizumab by thermosensitive biodegradable and biocompatible hydrogel.","volume":"13","author":"Wang","year":"2012","journal-title":"Biomacromolecules"},{"key":"B207","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1002\/jbm.a.36450","article-title":"Nanoceria-loaded injectable hydrogels for potential age-related macular degeneration treatment.","volume":"106","author":"Wang","year":"2018","journal-title":"J. Biomed. Mater. Res. Part A"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08690-4","article-title":"Intravenous treatment of choroidal neovascularization by photo-targeted nanoparticles.","volume":"10","author":"Wang","year":"2019","journal-title":"Nat. Commun."},{"key":"B209","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/nyas.12824","article-title":"Development of a dexamethasone intravitreal implant for the treatment of noninfectious posterior segment uveitis.","volume":"1358","author":"Whitcup","year":"2015","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"B210","author":"Wilkinson","year":"2017","journal-title":"Ryan\u2019s Retina -"},{"key":"B211","article-title":"Nanostructured porous silicon dioxide microparticles as an intravitreal injectable drug delivery system for avastin (Bevacizumab) lasting six months.","volume":"53","author":"William","year":"2012","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"B212","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.exer.2007.09.005","article-title":"Cadmium accumulation in the human retina: effects of age, gender, and cellular toxicity.","volume":"86","author":"Wills","year":"2008","journal-title":"Exp. Eye Res."},{"key":"B213","article-title":"Oxidative damage and age-related macular degeneration.","volume":"5","author":"Winkler","year":"1999","journal-title":"Mol. Vis."},{"key":"B214","year":"2018","journal-title":"Priority Eye Diseases."},{"key":"B215","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijbiomac.2013.05.034","article-title":"Sustained release of avastin\u00a7from polysaccharides cross-linked hydrogels for ocular drug delivery.","volume":"60","author":"Xu","year":"2013","journal-title":"Int. J. Biol.Macromol."},{"key":"B216","doi-asserted-by":"publisher","first-page":"4603","DOI":"10.1039\/c9bm01049a","article-title":"Sustained delivery of anti-VEGFs from thermogel depots inhibits angiogenesis without the need for multiple injections.","volume":"7","author":"Xue","year":"2019","journal-title":"Biomater. Sci."},{"key":"B217","doi-asserted-by":"publisher","first-page":"4676","DOI":"10.1021\/mp400487f","article-title":"Nanoparticles in porous microparticles prepared by supercritical infusion and pressure quench technology for sustained delivery of bevacizumab.","volume":"10","author":"Yandrapu","year":"2013","journal-title":"Mol. Pharm."},{"key":"B218","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1080\/10837450.2018.1545236","article-title":"Silk fibroin nanoparticles for enhanced bio-macromolecule delivery to the retina.","volume":"24","author":"Yang","year":"2019","journal-title":"Pharm. Dev. Technol."},{"key":"B219","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.preteyeres.2004.02.003","article-title":"Drug delivery systems for vitreoretinal diseases.","volume":"23","author":"Yasukawa","year":"2004","journal-title":"Prog. Retin. Eye Res."},{"key":"B220","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.7434025","article-title":"pH-sensitive liposomes: possible clinical implications.","volume":"210","author":"Yatvin","year":"1980","journal-title":"Science"},{"key":"B221","doi-asserted-by":"publisher","first-page":"653","DOI":"10.3980\/j.issn.2222-3959.2015.04.02","article-title":"Pharmacokinetics and distributions of bevacizumab by intravitreal injection of bevacizumab-PLGA microspheres in rabbits.","volume":"8","author":"Ye","year":"2015","journal-title":"Int. J. Ophthalmol."},{"key":"B222","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF02980037","article-title":"Control of encapsulation efficiency and initial burst in polymeric microparticle systems.","volume":"27","author":"Yeo","year":"2004","journal-title":"Arch. Pharm. Res."},{"key":"B223","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ijpharm.2014.04.053","article-title":"In situ covalently cross-linked PEG hydrogel for ocular drug delivery applications.","volume":"470","author":"Yu","year":"2014","journal-title":"Int. J. Pharm."},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.4.2.5","article-title":"Injectable chemically crosslinked hydrogel for the controlled release of bevacizumab in vitreous: a 6-month in vivo study.","volume":"4","author":"Yu","year":"2015","journal-title":"Transl. Vis. Sci. Technol."},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10128","article-title":"Long-term therapeutic effect in nonhuman primate eye from a single injection of anti-VEGF controlled release hydrogel.","volume":"4","author":"Yu","year":"2019","journal-title":"Bioeng. Transl. Med."},{"key":"B226","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1086\/431426","article-title":"Strong association of the Y402H variant in complement factor h at 1q32 with susceptibility to age-related macular degeneration.","volume":"77","author":"Zareparsi","year":"2005","journal-title":"Am. J. Hum. Genet."}],"container-title":["Frontiers in Bioengineering and Biotechnology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2020.549089\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T14:58:12Z","timestamp":1604415492000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fbioe.2020.549089\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,3]]},"references-count":226,"alternative-id":["10.3389\/fbioe.2020.549089"],"URL":"https:\/\/doi.org\/10.3389\/fbioe.2020.549089","relation":{},"ISSN":["2296-4185"],"issn-type":[{"value":"2296-4185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,3]]},"article-number":"549089"}}